Thomas Cerny Kantonsspital St.Gallen thomas.cerny@kssg.ch www ...
Thomas Cerny Kantonsspital St.Gallen thomas.cerny@kssg.ch www ...
Thomas Cerny Kantonsspital St.Gallen thomas.cerny@kssg.ch www ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Weiterbildung LUKS Onkologie, 4/12<br />
Sammeln (Register) zur Plausibilisierung<br />
(ASCO 2010 Bay abstract 10097: a national registry for the off-label use of targeted<br />
therapies in pts with malignant mesen<strong>ch</strong>ymal tumors: a retrospective analysis)<br />
• Zeitraum: 1 Jahr Okt 2008-2009<br />
• N: 162, 52% male, median age 47y<br />
• Median n of previous therapies: 4<br />
• LM: 20%, GIST 13%, Chordoma 8%, Angiosarcoma 7%, PNET 6%<br />
• PFS at 6m: 35%, >PFS at 12m: 23%<br />
• 2 CR: 1x PNET (Sunitinib), 1x PEComa (Temsirolimus)<br />
• 80% alive at 6 months<br />
• No toxic deaths, G4 Tox: 4.5%<br />
Conclusions: off label commonly used in mesen<strong>ch</strong>ymal tumors, toxicity<br />
profile acceptable, identification of usefull observations for rarest<br />
tumors. i.e. PECOma now 3 patients on temsirolimus....
Change language